Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCrimson Tide Regulatory News (TIDE)

Share Price Information for Crimson Tide (TIDE)

Share Price is delayed by 15 minutes
Get Live Data
92.50    5.00 (5.71%)
Bid:
90.00
Ask:
95.00
Spread: 5.00 (5.556%)
Market Cap: £6.08m
TIDE Live PriceLast checked at - London Stock Exchange

Intraday Crimson Tide Share Chart

Pharmaceutical Verification Pilot

14 Jul 2016 07:00

RNS Number : 1316E
Crimson Tide PLC
14 July 2016
 

Crimson Tide PLC

 

("Crimson Tide" or the 'Company')

 

Crimson Tide selected for pharmaceutical verification pilot

 

Crimson Tide (TIDE), the AIM-quoted provider of mpro5 - Smart Mobility as a Service, has won a contract for the initial stage of a significant healthcare pilot project in Asia for the serialisation and verification of pharmaceutical products. The pilot project is being implemented under the auspices of the Asia Pacific Economic Cooperation (APEC) Life Sciences Innovation Forum (LSIF), Committee on Trade and Investment (CTI) and Business Advisory Council (ABAC).

 

Selected by a consortium of pharma organisations, the technology platform for the demonstration phase of the pilot project will leverage mpro5 to scan pharmaceutical products, generating an anonymous verification request to the product's manufacturer. The pilot project seeks to demonstrate for the first time the ability to verify serialised pharmaceutical products from various scan locations to source data stored in distributed databases using global data standards. The pilot also seeks to promote harmonisation by demonstrating the ability to use a single or reproducible data gateway in multiple countries.

 

mpro5 provides barcode scanning and cloud-based synchronisation services via Microsoft Azure, renowned for its reliability, scalability and security. This enables real-time information upload, quick verifications and multi-way data request transmittals.

 

Barrie Whipp, Executive Chairman of Crimson Tide, said: "The global impact of drug serialisation and verification cannot be underestimated. I am delighted that we have been chosen to help in this pilot project in Asia, as it opens up significant opportunities in the pharma world."

 

ends

 

For further information:

 

Crimson Tide plc

 

Barrie Whipp 01892 542 444

Steve Goodwin

 

WH Ireland

 

James Joyce /James Bavister 020 7220 1666

Allerton Communications

Peter Curtain 020 3137 2500

peter.curtain@allertoncomms.co.uk 

 

Notes to editors

Founded in 1996 and quoted on AIM since 2006, Crimson Tide plc is the provider of mpro5 - Smart Mobility as a Service (SMaaS). mpro5 is delivered on smartphones, tablets and PDAs, and enables companies to transform their businesses and strengthen their workforces.

Crimson Tide offers a global service, working with some of the world's leading companies, tailoring mpro5 to suit customer needs. Developed over 10 years by its world-class team, mpro5 is the smart choice for organisations large and small that want to improve productivity and save money.

mpro5 is a platform-agnostic mobility suite fully hosted on Microsoft Azure, so customers are quickly up and running and the service is scalable and robust. It is provided on subscription, so clients can immediately see a return on their investment.

mpro5 not only helps people improve their day-to-day working methods while saving employers money, it also saves lives, by enabling haemophilia patients to verify the safety of their medication before use. mpro5 clients come from a diverse range of industries allowing the Company to listen, share and find the best solution for all mobility needs.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTEAPXDFFLKEFF
Date   Source Headline
20th Oct 20097:00 amRNSChange of Adviser
1st Oct 20099:39 amRNSTotal Voting Rights
8th Sep 20097:00 amRNSDisposal of part of trade in Ireland
2nd Sep 20097:01 amRNSBlocklisting Interim Review
2nd Sep 20097:00 amRNSExercise of Warrants and Director Dealing
11th Aug 20095:45 pmRNSHalf Yearly Report (Replacement)
11th Aug 20097:00 amRNSHalf Yearly Report
30th Jun 20091:00 pmRNSResult of AGM
16th Jun 20097:00 amRNSAcquisition of Trade
9th Jun 200910:10 amRNSAnnual Financial Report
8th Jun 20097:00 amRNSFinal Results
29th May 20093:53 pmRNSHolding(s) in Company
28th May 20097:00 amRNSYes Telecom Partnership
1st May 20091:13 pmRNSTotal Voting Rights
1st May 20091:11 pmRNSBlocklisting Interim Review
20th Jan 20092:49 pmRNSDirector/PDMR Shareholding
6th Nov 200811:47 amRNSGrant of Options
31st Oct 20087:00 amRNSBlocklisting Interim Review
25th Sep 20082:20 pmRNSInterim Results - Correction
25th Sep 20087:00 amRNSInterim Results
6th Aug 20087:00 amRNSBorrowing Facility
25th Jul 200812:20 pmRNSResult of AGM
21st Jul 20087:00 amRNSDirector/PDMR Shareholding
30th Jun 20088:51 amRNSAnnual Report and Accounts
30th Jun 20087:00 amRNSPreliminary Results
30th May 20084:30 pmRNSTotal Voting Rights
1st May 200810:44 amRNSIssue of Equity
1st May 200810:37 amRNSBlocklisting Interim Review
30th Apr 20084:30 pmRNSTotal Voting Rights
25th Apr 200812:23 pmRNSResult of General Meeting
24th Apr 20087:01 amRNSEntered for Microsoft Award
23rd Apr 20083:58 pmRNSPlacing & Borrowing Facility
10th Apr 20084:22 pmRNSNotice of General Meeting
4th Apr 20085:41 pmRNSDirector/PDMR Shareholding
18th Feb 20087:00 amRNSContract Win - Heatons & DL&T
28th Jan 20087:01 amRNSContract Win - Ski Club
10th Dec 20077:01 amRNSContract Win - Knight Frank
31st Oct 20074:31 pmRNSTotal Voting Rights
31st Oct 20074:30 pmRNSBlocklisting Interim Review
27th Sep 20078:00 amRNSInterim Results
24th Aug 20072:28 pmRNSHolding(s) in Company
16th Aug 20073:14 pmRNSHolding(s) in Company
13th Aug 20075:38 pmRNSAim Rule 26 Information
19th Jul 20077:01 amRNSMicrosoft Partner Conference
29th Jun 20074:30 pmRNSTotal Voting Rights
18th Jun 20077:01 amRNSNew business partnership
5th Jun 20073:59 pmRNSShare Placing
5th Jun 20072:06 pmRNSGranting of share options
5th Jun 200711:27 amRNSAGM Statement
1st May 20077:01 amRNSBlocklisting Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.